Tumor 3′-deoxy-3′-18F-fluorothymidine ( 18F-FLT) uptake by PET correlates with thymidine kinase 1 expression: Static and kinetic analysis of 18F-FLT PET studies in lung tumors

Journal of Nuclear Medicine

Volumn 52, Issue 8, 2011, Pages 1181-1188

  Brockenbrough, J Scott ^a   Souquet, Timothee ^a   Morihara, Janice K ^a   Stern, Joshua E ^a   Hawes, Stephen E ^a   Rasey, Janet S ^a   Leblond, Antoine ^a   Wiens, Linda W ^a   Feng, Qinghua ^a   Grierson, John ^a   Vesselle, Hubert ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

3 deoxy 3 fluorothymidine; 18F FLT; Lung tumors; Positron emission tomography (PET); Thymidine kinase 1; Tumor proliferation

Indexed keywords

3' FLUOROTHYMIDINE F 18; KI 67 ANTIGEN; THYMIDINE KINASE 1; FLUORODEOXYGLUCOSE F 18; THYMIDINE KINASE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RETENTION; DRUG UPTAKE; ENZYME ACTIVITY; FEMALE; FROZEN SECTION; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; BIOSYNTHESIS; CELL CYCLE; CELL PROLIFERATION; KINETICS; LUNG TUMOR; METHODOLOGY; PATHOLOGY; PROGNOSIS; SCINTISCANNING; TIME;

CELL CYCLE; CELL PROLIFERATION; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; KINETICS; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; THYMIDINE KINASE; TIME FACTORS;

EID: 80051685501     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.089482     Document Type: Article

References (39)

1. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336. (Pubitemid 28512118)
2. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217. (Pubitemid 34988769)
3. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol. 2004;31:829-837. (Pubitemid 39297680)
4. Langen P, Etzold G, Hintsche R, Kowollick G. 3′-deoxy-3′- fluorothymidine, a new selective inhibitor of DNA synthesis. Acta Biol Med Ger. 1969;23:759-766.
5. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 1991;266:9032-9038. (Pubitemid 21906614)
6. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808-818.
7. 3H-FMAU in proliferating and nonproliferating human tumor cells. J Nucl Med. 2010;51:1464-1471.
8. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350-8358.
9. Ke PY, Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol. 2004;24:514-526.
10. Brockenbrough JS, Rasey JS, Grierson JR, Wiens LW, Vesselle H. A simple quantitative assay for the activity of thymidine kinase 1 in solid tumors. Nucl Med Biol. 2007;34:619-623. (Pubitemid 47248287)
11. Kristensen T, Jensen HK, Munch-Petersen B. Overexpression of human thymidine kinase mRNA without corresponding enzymatic activity in patients with chronic lymphatic leukemia. Leuk Res. 1994;18:861-866. (Pubitemid 24338181)
12. 18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging. 2005;32:257-263.
13. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027-2032. (Pubitemid 40022149)
14. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy- 3′fluorothymidine uptake. Nucl Med Biol. 2004;31:419-423. (Pubitemid 38490741)
15. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315-3323.
16. Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F] fluorothymidine. Semin Nucl Med. 2007;37:429-439. (Pubitemid 47498262)
17. 18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. J Nucl Med. 2010;51:713-719.
18. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837-3844.
19. Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy-3′-[F-18] fluorothymidine: [F-18]FLT for imaging cellular proliferation in vivo. Nucl Med Biol. 2000;27:143-156. (Pubitemid 30204569)
20. 18F]-FLT). J Radioanal Nucl Chem. 2000;243:843-846.
21. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med. 2005;46:274-282. (Pubitemid 43073435)
22. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med. 2005;46:371-380. (Pubitemid 43073449)
23. Brockenbrough JS, Morihara JK, Hawes SE, et al. Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation. J Histochem Cytochem. 2009;57:1087-1097.
24. Yusa T, Yamaguchi Y, Ohwada H, et al. Activity of the cytosolic isozyme of thymidine kinase in human primary lung tumors with reference to malignancy. Cancer Res. 1988;48:5001-5006.
25. Greengard O, Head JF, Goldberg SL, Kirschner PA. Biochemical measure of the volume doubling time of human pulmonary neoplasms. Cancer. 1985;55:1530-1535. (Pubitemid 15140690)
26. Hengstschläger M, Knöfler M, Müllner EW, Ogris E, Wintersberger E, Wawra E. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem. 1994;269:13836-13842. (Pubitemid 24191128)
27. Hengstschläger M, Mudrak I, Wintersberger E, Wawra E. A common regulation of genes encoding enzymes of the deoxynucleotide metabolism is lost after neoplastic transformation. Cell Growth Differ. 1994b;5:1389-1394. (Pubitemid 24381528)
28. Mikulits W, Hengstschläger M, Sauer T, Wintersberger E, Müllner EW. Overexpression of thymidine kinase mRNA eliminates cell cycle regulation of thymidine kinase enzyme activity. J Biol Chem. 1996;271:853-860. (Pubitemid 26034937)
29. Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. J Biol Chem. 2010;285:27327-27335.
30. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948-1958.
31. 18Ffluorothymidine in patients with gliomas. J Nucl Med. 2006;47:1612-1621.
32. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun. 2001;280:951-959. (Pubitemid 32924526)
33. Hubeek I, Giovannetti E, Broekhuizen AJ, Pastor-Anglada M, Kaspers GJ, Peters GJ. Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples. Nucleosides Nucleotides Nucleic Acids. 2008;27:787-793. (Pubitemid 351948588)
34. Nottebrock H, Then R. Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol. 1977;26:2175-2179. (Pubitemid 8183884)
35. Liekens S, Bronckaers A, Pérez-Pérez MJ, Balzarini J. Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem Pharmacol. 2007;74:1555-1567. (Pubitemid 47614960)
36. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45:695-700.
37. 18F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography. Mol Imaging Biol. 2010;13:321-331.
38. Paproski RJ, Ng AM, Yao SY, Graham K, Young JD, Cass CE. The role of human nucleoside transporters in uptake of 3′-deoxy-3′- fluorothymidine. Mol Pharmacol. 2008;74:1372-1380.
39. Paproski RJ, Wuest M, Jans HS, et al. Biodistribution and uptake of 3′-deoxy-3′- fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. J Nucl Med. 2010;51:1447-1455.